The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes

Cardiology (Switzerland)

Volumn 125, Issue 3, 2013, Pages 182-191

  Tomek, Aleš ^a,b   Ma͗oška, Václav ^b   Kolářová, Tereza ^b   Neumann, Jiří ^c   Šrámek, Martin ^a   Šarbochová, Ivana ^a   Táborský, Luděk ^b   Bojar, Martin ^a   Goetz, Petr ^a   Serebruany, Victor L ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NA HOMOLCE HOSPITAL   (Czech Republic)

^c Chomutov Hospital   (Czech Republic)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bleeding risk; CYP2C9 gene; Major bleeding event; VKORC1 gene; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AGED; ALLELE; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84878923105     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000350407     Document Type: Article

References (22)

1. Wadelius M, Chen L, Lindh J, Eriksson N, Ghori M, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113: 784-792.
2. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
3. Tomek A, Matoska V, Eisert C, Serebruany VL: Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations. Am J Ther 2011; 18:e55-e66.
4. Higashi M, Veenstra DL, Kondo LM, Wittkovsky AK, Srinouanprachanhto SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-1698.
5. Joffe H, Xu R, Johnson F, Longtine J, Kucher N, Goldhaber S: Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-1128.
6. Meckley L, Wittkowsky A, Rieder M, Rettie A, Veenstra D: An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin patients. Thromb Haemost 2008; 100: 229-239.
7. Aithal G, Day C, Kesteven P, Daly A: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
8. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G: Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-778.
9. Rieder M, Reiner A, Gage B, Nickerson D, Eby C, McLeod H, Blough D, Thummel K, Veenstra D, Rettie A: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
10. Sconce E, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F: The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
11. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-270.
12. Schwarz U, Ritchie M, Bradford Y, Li C, Dudek S, Frye-Anderson A, Kim R, Roden D, Stein C: Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
13. Limdi NA, Mcgwin G, Goldstein J, Beasley T, Arnett DK, Adler BK, Baird MF, Acton R: Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 2008; 83: 312-321.
14. Lindh JD, Holm L, Dahl ML, Alfredsson L, Rane A: Incidence and predictors of severe bleeding during warfarin treatment. J Thromb Thrombolysis 2008; 25: 151-159.
15. Levine MN, Raskob G, Kearon C, Schulman S: Hemorrhagic complications of anticoagulant treatment. Chest 2004; 126: 287S-310S.
16. Database of Single Nucleotide Polymorphisms (DBSNP). Bethesda, National Center for Biotechnology Information, National Library of Medicine (DBSNP build ID: 119/137). http://www.Ncbi.Nlm.Nih.Gov/snp/snp-ref.Cgi?Rs=9934438.
17. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
18. Grønnesby JK, Borgan Ø: A method for checking regression models in survival analysis based on the risk score. Lifetime Data Anal 1996; 2: 315-328.
19. May S, Hosmer DW: A cautionary note on the use of the Grønnesby and Borgan goodnessof-fit test for the Cox proportional hazards model. Lifetime Data Anal 2004; 10: 283-291.
20. Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
21. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR: Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PloS One 2012; 7:e44064.
22. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RELY trial. Lancet 2010; 376: 975-983.